Figure 6
From: Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
PROSTVAC immunotherapy expands highly activated CD8 effector T cells in the tumor and improves the T eff :T reg cell ratios. (A) Schematic for the characterization of effector and memory cells. Pie charts are weighted in size to reflect the numbers of detected cells (numbers below indicate total number of CD8 T cells/million tumor cells). (B) CD4 and (C) CD8 Teff :Treg ratios were calculated by dividing the number of CD4+ FoxP3- or CD8+ T cells by the number of CD4+ FoxP3+ Treg cells. Graphs show representative data from four independently performed experiments.